Runway Growth Finance (RWAY) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
8 Jul, 2026Executive summary
Delivered Q4 2025 total investment income of $30 million and net investment income of $11.6 million, both down sequentially and year-over-year.
Completed 7 investments totaling $42.9 million in high-growth sectors, including technology, healthcare, and consumer.
Announced acquisition of SWK Holdings, expected to close in early April 2026, to enhance portfolio diversification and healthcare exposure.
Achieved 31 consecutive quarterly distributions, reflecting stable dividends and strong operational consistency.
Platform AUM reached approximately $10.2B, with global investment exposure across the US, UK, and Canada.
Financial highlights
Q4 2025 total investment income: $30 million; net investment income: $11.6 million, down from $36.7 million and $15.7 million in Q3 2025 and from $33.8 million and $14.6 million in Q4 2024.
Net asset value (NAV) per share at Q4 end: $13.42, down from $13.55 at Q3 end and $13.79 at year-end 2024.
Portfolio fair value: $927.4 million across 56 companies, a 2% decrease from Q3 and down from $1,076.8 million a year earlier.
Debt portfolio yield: 14.2% in Q4 2025.
Operating expenses: $18.4 million in Q4, down from $21 million in Q3 and $19.2 million in Q4 2024.
Outlook and guidance
Pipeline for Q1 2026 is stronger than the prior year, with optimism for increased origination activity.
SWK Holdings acquisition expected to generate mid single-digit run-rate NII accretion in the first full quarter post-closing.
Pro-forma leverage anticipated just under 1.2x, supporting expanded ROE and dividend coverage.
Dividend set at $0.33 per share for Q1 2026, with confidence in sustainability.
Latest events from Runway Growth Finance
- Q2 2024 featured strong yields, new investments, and active capital return programs.RWAY
Q2 20249 Jul 2026 - NAV per share rose to $13.79 as BC Partners Credit integration enhanced growth capacity.RWAY
Q4 20248 Jul 2026 - SWK acquisition expands healthcare exposure as Q1 income dips and share repurchase is launched.RWAY
Q1 20268 May 2026 - Annual meeting to elect directors and ratify Deloitte as auditor, with strong governance in place.RWAY
Proxy filing29 Apr 2026 - Shareholders will vote on two director nominees and auditor ratification at the June 2026 virtual meeting.RWAY
Proxy filing29 Apr 2026 - Q3 2024 saw $75.3M in new loans, strong yields, and a strategic adviser acquisition pending.RWAY
Q3 202414 Jan 2026 - $220M NAV-for-NAV merger boosts healthcare exposure and scale, closing by early 2026.RWAY
M&A Announcement7 Jan 2026 - Vote sought on new advisory agreement, director election, and adjournment; no fee or strategy changes.RWAY
Proxy Filing2 Dec 2025 - Shareholders will vote on director elections and auditor ratification at the 2024 virtual meeting.RWAY
Proxy Filing2 Dec 2025